Abstract
Recently, Forde et al . reported in the New England Journal of Medicine a pilot study in which two neoadjuvant doses of the PD-1 inhibitor nivolumab were administered in a preoperative fashion to 21 patients with untreated, surgically resectable early (stage I–IIIA) non-small cell lung cancer (NSCLC) (1). Surgery was performed 4 weeks after the first dose of nivolumab.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have